What is Zacks Research's Forecast for Perrigo Q3 Earnings?

Key Points

• Zacks Research has downgraded its Q3 2025 earnings estimate for Perrigo to $0.76 per share, down from a previous estimate of $0.79.
• Several analysts have adjusted their ratings and price targets for Perrigo, with Wall Street Zen changing their view from "buy" to "hold" and Canaccord Genuity lowering its price target from $42.00 to $40.00.
• Perrigo recently declared a quarterly dividend of $0.29 per share, reflecting a 4.9% dividend yield, with the ex-dividend date falling on August 29th.

Perrigo Company plc (NYSE:PRGO - Free Report) - Investment analysts at Zacks Research dropped their Q3 2025 earnings estimates for shares of Perrigo in a report released on Wednesday, August 27th. Zacks Research analyst Team now expects that the company will earn $0.76 per share for the quarter, down from their prior forecast of $0.79. The consensus estimate for Perrigo's current full-year earnings is $2.56 per share. Zacks Research also issued estimates for Perrigo's Q2 2026 earnings at $0.76 EPS and Q3 2026 earnings at $0.80 EPS.

Several other analysts also recently commented on the stock. JPMorgan Chase & Co. decreased their target price on shares of Perrigo from $38.00 to $35.00 and set an "overweight" rating for the company in a research report on Thursday, August 7th. Wall Street Zen downgraded shares of Perrigo from a "buy" rating to a "hold" rating in a research report on Sunday, August 24th. Finally, Canaccord Genuity Group decreased their target price on shares of Perrigo from $42.00 to $40.00 and set a "buy" rating for the company in a research report on Thursday, August 7th. Two equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $33.00.

Perrigo Stock Down 0.7%

PRGO stock traded down $0.17 during trading hours on Monday, hitting $23.16. The company's stock had a trading volume of 381,769 shares, compared to its average volume of 1,469,074. The company has a quick ratio of 1.24, a current ratio of 2.32 and a debt-to-equity ratio of 0.81. The company has a market capitalization of $3.19 billion, a PE ratio of -40.02 and a beta of 0.48. Perrigo has a 12 month low of $21.03 and a 12 month high of $30.93. The stock has a 50 day moving average price of $25.63 and a two-hundred day moving average price of $26.17.

Perrigo (NYSE:PRGO - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported $0.57 EPS for the quarter, missing the consensus estimate of $0.59 by ($0.02). The business had revenue of $1.06 billion during the quarter, compared to the consensus estimate of $1.08 billion. Perrigo had a positive return on equity of 9.09% and a negative net margin of 1.86%.The business's revenue was down .9% on a year-over-year basis. During the same period in the prior year, the firm earned $0.53 earnings per share.

Institutional Investors Weigh In On Perrigo

Hedge funds have recently modified their holdings of the business. Geneos Wealth Management Inc. boosted its position in shares of Perrigo by 439.1% in the first quarter. Geneos Wealth Management Inc. now owns 965 shares of the company's stock valued at $27,000 after acquiring an additional 786 shares during the period. Huntington National Bank increased its position in shares of Perrigo by 237.8% during the second quarter. Huntington National Bank now owns 1,054 shares of the company's stock valued at $28,000 after purchasing an additional 742 shares during the period. MassMutual Private Wealth & Trust FSB increased its position in shares of Perrigo by 54.6% during the second quarter. MassMutual Private Wealth & Trust FSB now owns 1,201 shares of the company's stock valued at $32,000 after purchasing an additional 424 shares during the period. Hantz Financial Services Inc. increased its position in shares of Perrigo by 101.0% during the second quarter. Hantz Financial Services Inc. now owns 1,234 shares of the company's stock valued at $33,000 after purchasing an additional 620 shares during the period. Finally, Picton Mahoney Asset Management bought a new stake in shares of Perrigo during the first quarter valued at approximately $42,000. 95.91% of the stock is owned by institutional investors.

Insider Activity

In other Perrigo news, CFO Eduardo Guarita Bezerra acquired 3,000 shares of Perrigo stock in a transaction dated Monday, August 18th. The stock was bought at an average cost of $22.74 per share, with a total value of $68,220.00. Following the completion of the transaction, the chief financial officer owned 48,949 shares of the company's stock, valued at $1,113,100.26. The trade was a 6.53% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Geoffrey M. Parker acquired 4,375 shares of Perrigo stock in a transaction dated Monday, August 18th. The stock was acquired at an average cost of $22.97 per share, with a total value of $100,493.75. Following the completion of the transaction, the director directly owned 33,287 shares of the company's stock, valued at $764,602.39. This trade represents a 15.13% increase in their position. The disclosure for this purchase can be found here. Insiders have bought a total of 8,863 shares of company stock valued at $204,575 over the last 90 days. 0.70% of the stock is currently owned by company insiders.

Perrigo Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 16th. Stockholders of record on Friday, August 29th will be given a $0.29 dividend. The ex-dividend date of this dividend is Friday, August 29th. This represents a $1.16 dividend on an annualized basis and a dividend yield of 5.0%. Perrigo's dividend payout ratio (DPR) is currently -200.00%.

About Perrigo

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.